ClinicalTrials.gg
RecruitingNCT07098338LIBRAUpdated Oct 15, 2026

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Rilvegostomig and Ramucirumab in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Recruiting at 83 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
278
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
11th of 21
278 · median 278
Started
2025
with 3 others
Phase 2
7 of 21
3 open now
Primary completion
2029-04
later than 13 of 18 live
Registered
19th of 21
by date
Lead sponsor
11 of 21
AstraZeneca

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by planned enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 13 of the 18 other live ones, and was the 19th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Read the detailed description

The master protocol will include 3 sub-studies, each focused on a specific disease population.

  • Sub-study 1 will investigate rilvegostomig± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 ≥50%.
  • Sub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.
  • Sub-study 3 will investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+

Each sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Non-Small Cell Lung Cancer(NSCLC)
  • Antibody-Drug Conjugates (ADCs)
  • T-cell immunoreceptor with Ig and Immunoreceptor Tyrosine-based Inhibition Motif (ITIM) domains (TIGIT)
  • Programmed death-ligand 1 (PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age at the time of signing the ICF
  • performance status of 0 or 1
  • At least 1 lesion that qualifies as a 1.1 Target Lesion (TL) at baseline.
  • Adequate bone marrow and organ function
  • ≥ 12 weeks
  • Provision of acceptable tumour tissue

Specific Inclusion Criteria for Sub-Study 1 and Sub-Study 2:

  • or cytologically documented advanced or NSCLC
  • TC ≥ 1% (TC≥ 50% for sub-study 1, 1-49% for sub-study 2)
  • Absence of sensitizing EGFR mutations or ALK rearrangements. No known other Actionable Genomic Alterations(AGAs)

Specific Inclusion Criteria for Sub-Study 3:

  • Histologically or cytologically documented advanced or metastatic non-squamous NSCLC
  • Documented positive AGA and had progressed on prior targeted therapy

Exclusion criteria

Exclusion Criteria for All Sub-studies:

  • As judged by the investigator, any severe or uncontrolled systemic diseases, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol
  • Active or prior documented or inflammatory disorders
  • Persistent toxicities ( Grade ≥ 2) (NCI CTCAE v5.0) caused by previous anti cancer therapy, excluding alopecia.
  • Spinal cord compression or for sub-study 1 and sub-study 2. Unstable spinal cord compression for sub-study 3
  • Unstable
  • History of another primary .
  • Active infection, including TB and infections with , (verified by known positive HBsAg result), .
  • Uncontrolled or significant cardiac disease
  • Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2.
  • Prior exposure to immune-mediated therapy
  • History of uncontrolled hypertension, and active bleeding diseases, and high risks of bleeding and disorders of coagulation
  • Any concurrent anti-cancer treatment.
  • Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
278 participants (estimated)

Study arms

  • Experimental
    Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%

    Participants will receive rilvegostomig ± ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion

    Drug: Rilvegostomig · Drug: Ramucirumab

  • Experimental
    Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%

    Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion

    Drug: Rilvegostomig · Drug: Ramucirumab

  • Experimental
    Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC

    Participants will receive Dato-DXd + ramucirumab ± rilvegostomig until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion

    Drug: Rilvegostomig · Drug: Ramucirumab · Drug: Dato-DXd

Interventions

  • Rilvegostomig will be administered as IV infusion.

    Also known as: AZD2936

  • Ramucirumab will be administered as IV infusion.

    Also known as: Cyramza

  • Dato-DXd will be administered as IV infusion.

    Also known as: DS-1062

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AE) and serious adverse events (SAE)

    To assess the safety and tolerability

    Time frame: Through study completion, an average of 3 years

  2. Objective response rate (ORR)

    ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response) per RECIST 1.1

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Best Overall Response(BOR)

    BOR is the best response a participant has had following randomisation/start of dosing, but prior to starting any subsequent cancer therapy and up to and including RECIST progression or the last evaluable assessment in the absence of RECIST progression

    Time frame: Through study completion, an average of 3 years

  2. Change in Target Lesion Tumor Size

    The best percentage change from baseline in Target Lesion tumour size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST 1.1 assessments

    Time frame: Through study completion, an average of 3 years

  3. Progression free survival (PFS)

    PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1.

    Time frame: Through study completion, an average of 3 years

  4. Disease Control Rate(DCR) at 12 Weeks

    DCR at 12 weeks is defined as the percentage of participants who have a best objective response of confirmed CR or PR or who have SD for at least 11 weeks after start of treatment (to allow for an early assessment within the assessment window).

    Time frame: From Day 1 pre-dose to 12 weeks

  5. Duration Of Response (DoR)

    The DoR is defined as the time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression).

    Time frame: Through study completion, an average of 3 years

  6. Overall Survival(OS)

    OS is defined as the time from the start of treatment until death due to any cause.

    Time frame: Through study completion, an average of 3 years

  7. Serum concentration

    To assess the serum concentration of the novel anti-cancer agents in combination.

    Time frame: Through study completion, an average of 3 years

  8. Maximum plasma drug concentration (Cmax)

    To assess the Cmax of the novel anti-cancer agents in combination.

    Time frame: Through study completion, an average of 3 years

  9. Immunogenicity of study interventions in participants receiving treatment

    Presence of Anti Drug Antibodies(ADAs) for study interventions in serum/plasma

    Time frame: Through study completion, an average of 3 years

07

Study locations

58 of 83 sites recruiting
  • Research Site
    Santa Monica, California 90404, United States
    Recruiting
  • Research Site
    Santa Rosa, California 95403, United States
    Not yet recruiting
  • Research Site
    Atlanta, Georgia 30318, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21231, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77090, United States
    Not yet recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Heidelberg, 3084, Australia
    Not yet recruiting
  • Research Site
    Nedlands, 6009, Australia
    Not yet recruiting
  • Research Site
    Woodville, 5011, Australia
    Not yet recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Deyang, 618000, China
    Recruiting
  • Research Site
    Dongguan, 523059, China
    Recruiting
  • Research Site
    Fuzhou, 350014, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Guangzhou, 510080, China
    Recruiting
  • Research Site
    Guangzhou, 510100, China
    Recruiting
  • Research Site
    Hangzhou, 310014, China
    Recruiting
  • Research Site
    Hefei, 230022, China
    Recruiting
  • Research Site
    Linyi, 276001, China
    Recruiting
  • Research Site
    Mianyang, 621000, China
    Recruiting
  • Research Site
    Nanchang, 330000, China
    Recruiting
  • Research Site
    Nanchang, 330006, China
    Recruiting
  • Research Site
    Shantou, China
    Recruiting
  • Research Site
    Shenyang, 110042, China
    Recruiting
  • Research Site
    Wuhan, 430022, China
    Recruiting
  • Research Site
    Zhengzhou, 450000, China
    Recruiting
  • Research Site
    Zhengzhou, 450008, China
    Recruiting
  • Research Site
    Zhuhai, 519000, China
    Recruiting
  • Research Site
    Avignon, 84902, France
    Not yet recruiting
  • Research Site
    Paris, 75005, France
    Not yet recruiting
  • Research Site
    Rennes, 35000, France
    Not yet recruiting
  • Research Site
    Saint-Herblain, 44805, France
    Not yet recruiting
  • Research Site
    Suresnes, 92150, France
    Recruiting
  • Research Site
    Aviano, 33081, Italy
    Not yet recruiting
  • Research Site
    Catania, 95123, Italy
    Not yet recruiting
  • Research Site
    Meldola, 47014, Italy
    Not yet recruiting
  • Research Site
    Milan, 20141, Italy
    Not yet recruiting
  • Research Site
    Milan, 35128, Italy
    Not yet recruiting
  • Research Site
    Orbassano, 10043, Italy
    Not yet recruiting
  • Research Site
    Roma, 00144, Italy
    Not yet recruiting
  • Research Site
    Rozzano, 20089, Italy
    Not yet recruiting
  • Research Site
    Bunkyō City, 113-8677, Japan
    Recruiting
  • Research Site
    Fukuyama-shi, 722-0001, Japan
    Recruiting
  • Research Site
    Kobe, 650-0047, Japan
    Recruiting
  • Research Site
    Kurume-shi, 830-0011, Japan
    Recruiting
  • Research Site
    Kyoto, 602-8566, Japan
    Recruiting
  • Research Site
    Kyoto, 606-8507, Japan
    Recruiting
  • Research Site
    Osaka, 541-8567, Japan
    Recruiting
  • Research Site
    Sakaishi, 591-8555, Japan
    Recruiting
  • Research Site
    Shinjuku-ku, 162-8655, Japan
    Recruiting
  • Research Site
    Wakayama, 641-8510, Japan
    Recruiting
  • Research Site
    Yokohama, 236-0051, Japan
    Recruiting
  • Research Site
    Singapore, 119082, Singapore
    Recruiting
  • Research Site
    Singapore, 168583, Singapore
    Recruiting
  • Research Site
    Cheongju-si, 28644, South Korea
    Recruiting
  • Research Site
    Namdong-gu, 21565, South Korea
    Recruiting
  • Research Site
    Seongnam-si, 13496, South Korea
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    Seoul, 3722, South Korea
    Recruiting
  • Research Site
    Seoul, 5505, South Korea
    Recruiting
  • Research Site
    Suwon, 16247, South Korea
    Recruiting
  • Research Site
    Suwon, 16499, South Korea
    Recruiting
  • Research Site
    A Coruña, 15006, Spain
    Not yet recruiting
  • Research Site
    Madrid, 28041, Spain
    Not yet recruiting
  • Research Site
    Manresa, 08243, Spain
    Recruiting
  • Research Site
    Málaga, 29009, Spain
    Recruiting
  • Research Site
    Santander, 39008, Spain
    Recruiting
  • Research Site
    Valencia, 46010, Spain
    Not yet recruiting
  • Research Site
    Liuying, 736, Taiwan
    Recruiting
  • Research Site
    Taichung, 402, Taiwan
    Recruiting
  • Research Site
    Taichung, 40447, Taiwan
    Recruiting
  • Research Site
    Tainan, 70403, Taiwan
    Recruiting
  • Research Site
    Tainan, 710, Taiwan
    Recruiting
  • Research Site
    Taipei, 100, Taiwan
    Recruiting
  • Research Site
    Taipei, 110, Taiwan
    Recruiting
  • Research Site
    Taipei, 11217, Taiwan
    Recruiting
  • Research Site
    Taoyuan, 00333, Taiwan
    Recruiting
  • Research Site
    Bangkok, 10330, Thailand
    Recruiting
  • Research Site
    Bangkok, 10400, Thailand
    Not yet recruiting
  • Research Site
    Bangkok, 10700, Thailand
    Not yet recruiting
  • Research Site
    Banphaeo, 74120, Thailand
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2029, 43 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 43 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Aug 1, 2025
StartActual
Aug 7, 2025
Primary completionEst.
Apr 6, 2029
CompletionEst.
Apr 6, 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07098338
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Aug 1, 2025
Start date
Aug 7, 2025
Primary completion
Apr 6, 2029 (estimated)
Completion
Apr 6, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion